MAMohammad Amouzadeh-Lichahi

Mohammad Amouzadeh-Lichahi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohammad Amouzadeh-Lichahi has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence of metabolic syndrome among patients with multiple sclerosis: a systematic review and meta-analysis

    by Shahriar Ghodous, Saisree Reddy Adla Jala, Kavya Priya Somu, Nikitha Chellapuram, Artika Misra, Abinash Mahapatro, Mohammad Amouzadeh-Lichahi, Maryam Jafari, Amir Khanmirzaei, Mohammad Sammak Salekdeh, et al.

    Background: Metabolic syndrome (MetS) is a common metabolic condition that coexists with multiple sclerosis (MS), yet reported prevalence estimates vary across studies and populations. This study aims to report the prevalence of MetS among patients with MS. Methods: Observational studies reporting the prevalence of MetS among patients with MS were included. Pooled prevalence estimates were calculated using random-effects models. Results: The pooled prevalence of MetS among patients with MS was 25% (95% CI, 20–31%), with substantial heterogeneity ( I 2 = 71.87%). In subgroup analyses by MS diagnostic criteria, studies using the McDonald criteria reported a pooled prevalence of 29% (95% CI, 24–34%), and the study using International Classification of Primary Care, Second Edition (ICPC-2)/International Classification of Diseases, Ninth Revision (ICD-9) criteria reported 31% (95% CI, 25–37%). By MetS diagnostic criteria, pooled prevalence estimates were 30% (95% CI, 26–34%) using National Cholesterol Education Program Adult Treatment Panel III, 23% (95% CI, 17–31%) using International Diabetes Federation, and 16% (95% CI, 11–21%) using American Heart Association/National Heart, Lung, and Blood Institute criteria. By body mass index (BMI) category, pooled prevalence was 11% (95% CI, 2–26%) for BMI < 25, 31% (95% CI, 21–42%) for 25 ≤ BMI < 30, and 58% (95% CI, 42–73%) for BMI ≥ 30. By expanded disability status scale (EDSS) category, pooled prevalence was 28% (95% CI, 21–34%) for EDSS < 4 and 51% (95% CI, 19–83%) for EDSS ≥ 4. Conclusion: MetS is present in approximately one-quarter of patients with MS, although the precision of the estimate is limited by the small number of studies and substantial heterogeneity. Differences in study design, population characteristics, and diagnostic criteria may contribute to this variability. Further studies using standardized definitions and consistent reporting are needed to improve the comparability of prevalence estimates across settings.

  • Open Access

    Effect of whole-body vibration training on hand grip strength of older adults: a systematic review and meta-analysis of randomized controlled trials

    by Zahra Ahmadnia, Fariborz Mansour-Ghanaei, Mohammad Amouzadeh-Lichahi, Soheil Hassanipour, Farahnaz Joukar

    Background: Aging is linked to declining health and heightened vulnerability among older adults. Research indicates that strength training can provide therapeutic health benefits. This study aimed to determine how a whole-body vibration (WBV) training program affects hand grip strength (HGS) in older adults. Methods: An electronic search was conducted across the MEDLINE, Web of Science, Scopus, and Embase databases. The study included randomized controlled trials (RCTs) involving WBV interventions compared with a control group in individuals over 65 years old, and the outcome measured was HGS. Two researchers used a critical appraisal checklist informed by risk-of-bias visualization. The standardized mean differences for HGS were calculated using a random-effects model to compare outcomes between the experimental and control groups. This systematic review was registered in the International Prospective Register of Systematic Reviews (no. CRD420251120347). Results: A total of 2713 articles were identified, of which eight RCTs fulfilled the inclusion criteria. The meta-analysis indicated that WBV significantly enhanced HGS (SMD = 0.246; 95% CI: 0.043–0.043; P = 0.018). Conclusions: WBV seems to be an effective method for improving HGS in older adults.

  • Open Access

    Prevalence of metabolic syndrome among patients with Alzheimer disease

    by Mohammad Amouzad-Lichahi, Iliya Petkov, Aseel Smerat, Haider W. Alsarhan, Negin Letafatkar, Mahsa Abbasnejad-Ardehroudkenari, Saman Mohammadi, Maryam Jafari, Shahriar Ghodous, Ehsan Amini-Salehi

    Background: The relationship between metabolic syndrome (MetS) and Alzheimer disease (AD) has gained increasing attention in recent years, reflecting the growing recognition of metabolic factors in neurodegenerative conditions. The present study aims to estimate the prevalence of MetS in patients with AD. Methods: A systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A comprehensive literature search of PubMed, Scopus, and Web of Science was performed. Observational studies reporting the prevalence of MetS among patients with AD and/or providing comparative data with control groups were included. Pooled prevalence and odds ratios with 95% confidence intervals (CIs) were calculated using a random-effects model, and heterogeneity was assessed using the I 2 statistic. Subgroup and meta-regression analyses were also performed. Results: Nine studies were included. The pooled prevalence of MetS among patients with AD was 46.7% (95% CI: 28.0%–65.8%; I 2 = 97.11%). In subgroup analysis by continent, the prevalence was 26.1% (95% CI: 11.1%–44.4%) in Asia ( I 2 = 84.42%) and 52.8% (95% CI: 25.2%–79.5%) in Europe ( I 2 = 97.05%), while the estimate from North America was 72.2% (95% CI: 62.5%–81.0%) based on a single study. The comparative analysis showed an odds ratio of 1.64 (95% CI: 0.75–3.57), with no statistically significant association between AD and MetS. Meta-regression identified glucose as significantly associated with MetS prevalence (β = 0.022; P = .021). Conclusion: MetS was frequently observed among patients with AD; however, the pooled prevalence estimate should be interpreted cautiously because of substantial between-study heterogeneity. The comparative analysis did not demonstrate a statistically significant association between AD and MetS. Further studies using standardized definitions and more homogeneous populations are needed to clarify this relationship and the sources of heterogeneity.

  • Open Access

    Deep learning-based segmentation of abdominal aortic aneurysm: a systematic review and meta-analysis of performance and clinical applicability

    by Negin Letafatkar, Saisree Reddy Adla Jala, Kavya Priya Somu, Mohammad Amouzadeh-Lichahi, Gokhan Anil, Hariprasad Reddy Korsapati, Casra Saeedi, Behrad Eftekhari, Abinash Mahapatro, Maryam Jafari, et al.

    Background: Abdominal aortic aneurysm (AAA) management relies heavily on imaging for surveillance, treatment planning, and follow-up. Deep learning (DL)-based segmentation may improve the efficiency and reproducibility of AAA image analysis; however, reported performance varies across studies. This study aimed to systematically review and quantitatively summarize the performance of DL models for AAA-related segmentation. Methods: PubMed, Embase, Scopus, and Web of Science were searched for studies applying DL to AAA imaging in adults and reporting Dice score or intersection-over-union (IoU) as segmentation metrics. Each DL model evaluated on a held-out test set was treated as a separate model-level observation. Random-effects meta-analyses were used to pool Dice score and IoU. Subgroup analyses were performed by imaging modality, model category, and input dimensionality, and additional analyses provided structure-specific estimates for aneurysm sac, intraluminal thrombus (ILT), lumen, and EVAR-related segmentations. Results: Across all targets, overall segmentation performance was 0.81 (95% CI 0.78–0.83) for Dice score and 0.72 (95% CI 0.67–0.77) for IoU. In subgroup analyses by model category, pooled Dice scores were 0.83 (95% CI 0.80–0.86) for U-Net family models, 0.82 (95% CI 0.77–0.86) for transformer or hybrid models, and 0.76 (95% CI 0.72–0.81) for other convolutional neural networks. By imaging modality, Dice scores were 0.87 (95% CI 0.84–0.89) for contrast-enhanced CT (CECT), 0.83 (95% CI 0.78–0.88) for non-contrast CT (NCCT), 0.84 (95% CI 0.81–0.87) for MRI, 0.78 (95% CI 0.74–0.82) for CT angiography (CTA), and 0.95 (95% CI 0.92–0.98) for X-ray. IoU subgroup analyses showed broadly similar patterns by modality and model category. In structure-specific analyses, aneurysm sac segmentation achieved a pooled Dice of 0.87 (95% CI 0.85–0.89) and IoU of 0.80 (95% CI 0.68–0.93); ILT segmentation reached 0.72 (95% CI 0.62–0.81) and 0.67 (95% CI 0.57–0.77); lumen segmentation 0.84 (95% CI 0.73–0.95) and 0.92 (95% CI 0.80–1.00); and EVAR-related targets 0.76 (95% CI 0.67–0.86) and 0.66 (95% CI 0.55–0.77) for Dice and IoU, respectively. Conclusions: DL-based models demonstrate good segmentation performance for the AAA sac and lumen, indicating clinically acceptable accuracy for applications such as volumetric surveillance and surgical planning. Performance for ILT and EVAR-related structures is more variable, suggesting that human oversight remains advisable for these targets in clinical practice. These findings support the use of DL-based segmentation in research and highlight its potential for selected clinical applications. However, the evidence base remains heterogeneous and is derived from a limited number of studies, with most models lacking external validation. Larger, standardized, multicentre evaluations with robust external validation are needed to confirm and refine these estimates.

  • Open Access

    Artificial Intelligence and Healthcare Policy: A Bibliometric Analysis of Global Research Trends

    by Pegah Rashidian, Forough Heidarzad-Pahlaviani, Seyedsina Moghimnejadhosseini, Nikitha Chellapuram, Kavya Priya Somu, Saisree Reddy Adla Jala, Herby Jeanty, Satabdi Sahu, Abinash Mahapatro, Mahsa Talebzadeh, et al.

    Background: Artificial intelligence is increasingly influencing health care and policy, yet the global research landscape linking artificial intelligence and health care policy remains underexplored. This study aimed to map publication trends, major contributors, collaboration networks, citation structures, and emerging themes in this field. Methods: A bibliometric analysis was conducted using the Web of Science Core Collection. The search was performed on 3 May 2026, and covered publications from 2000 to 3 May 2026. The final dataset included 347 peer-reviewed English-language original research and review articles. Biblioshiny, VOSviewer, and CiteSpace were used to analyze publication trends, country and institutional contributions, author and journal productivity, collaboration networks, citation and co-citation structures, keyword patterns, and thematic evolution. Results: Publications increased markedly after 2020 and reached their highest annual output in 2025. The 2026 publication count was lower because data for that year were partial at the time of database retrieval. Researchers from 82 countries and 900 institutions contributed to the field, with the United States leading in output, followed by China, England, Canada, and India. Harvard Medical School was the most productive institution, whereas Harvard University had the highest institutional centrality. Frontiers in Public Health published the most articles, and PLOS ONE was the most frequently co-cited journal. The most cited article was “Artificial intelligence and the future of global health.” Key research themes included machine learning, COVID-19, health policy, risk, large language models, interpretable machine learning, neural network-assisted screening, socioeconomic perspectives, and public health applications. Conclusions: Research on artificial intelligence and health care policy has expanded rapidly, particularly in recent years, and is increasingly centered on predictive modeling, public health decision-making, and emerging artificial intelligence technologies. These findings highlight influential contributors, evolving themes, and future directions for researchers, policymakers, and health care leaders.

  • Open Access

    Diagnostic performance of machine learning and deep learning algorithms for thyroid cancer metastasis: a systematic review and meta-analysis

    by Mohammad Amouzadeh Lichahi, Saeed Anvari, Hossein Hemmati, Ervin Zadgari, Maryam Jafari, Seyedeh Mohadeseh Mosavi Mirkalaie, Mohaya Farzin, Amirhossein Larijani

    Metastasis significantly influences prognosis in thyroid cancer, especially in papillary thyroid carcinoma. With the rise of artificial intelligence (AI) i


  • Open Access

    Prevalence of nonalcoholic fatty liver disease in rheumatoid arthritis: An updated systematic review and meta-analysis

    by Abinash Mahapatro, Maryam Jafari, Herby Jeanty, Satabdi Sahu, Fatemeh Eslampanah, Mohammad Amouzadeh-Lichahi, Mohit Mirchandani, Nakka Raghuma, Dhruvan Patel, Elan Mohanty, et al.

    Background: Rheumatoid arthritis (RA) is a chronic autoimmune disorder associated with various comorbidities, including nonalcoholic fatty liver disease (NAFLD). The prevalence of NAFLD in RA patients remains inconsistently reported, necessitating a comprehensive meta-analysis to estimate its true prevalence. This study aimed to assess the prevalence of NAFLD in patients with RA by synthesizing data from multiple studies. Methods: A systematic search was performed across PubMed, Scopus, and Web of Science for studies published up to January 2025. Eligible studies that reported on the prevalence of NAFLD in RA patients were included. A random-effects model was applied, and sensitivity analyses were conducted to test the robustness of the findings. Statistical analyses were performed using Comprehensive Meta-Analysis Software (CMA) version 4 Results: The pooled prevalence of NAFLD/nonalcoholic steatohepatitis (NASH) in RA patients was found to be 22.8% (95% CI = 7.8%–50.8%) with substantial heterogeneity ( I ² = 99.52%). The prediction interval for the prevalence of NAFLD/NASH ranged from 1% to 99%. Subgroup analysis showed varying prevalence rates based on diagnostic modalities: 33.3% for FibroScan, 43.9% for liver biopsy, and 30.5% for ultrasonography. Conclusion: The prevalence of NAFLD is remarkable in RA patients, with varying rates depending on diagnostic methods. The substantial heterogeneity observed across studies, reflected in the wide range of the prediction interval, underscores the need for further studies to provide a more precise estimate. Given the notable prevalence of NAFLD/NASH in RA patients, clinicians are suggested to consider this issue by implementing regular liver screening as a valuable part of RA patient care. More studies are essential to offer a clearer and more consistent understanding of NAFLD/NASH in this population.